Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.

Shai A, Wildiers H, Venieri C, Pogoda K, Linderholm B, Lambertini M, Matos L, De Maio D'Esposito E, Hajjaji N, Matos E, González Cortijo L, Fotia G, Fortuna A, Sella T, Gouveia H, Rosset L, Constantinidou A, Angeli E, Cicin I, Tjan-Heijnen V, Ruyssers N, Demasure S, Abu Remilah A, Huygh G, Paluch-Shimon S, Chiappe E, Shirron N, Neven P, Artac M, Kilictas B, Baranseh J, Vicente-Rubio E, Atci M, Amato O, van Duijnhoven F

Open source

DOI
10.1016/j.breast.2025.104669
Published
2026 Feb
Container
Breast (Edinburgh, Scotland)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2025.104669,
  title = {Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.},
  author = {Shai A and Wildiers H and Venieri C and Pogoda K and Linderholm B and Lambertini M and Matos L and De Maio D'Esposito E and Hajjaji N and Matos E and González Cortijo L and Fotia G and Fortuna A and Sella T and Gouveia H and Rosset L and Constantinidou A and Angeli E and Cicin I and Tjan-Heijnen V and Ruyssers N and Demasure S and Abu Remilah A and Huygh G and Paluch-Shimon S and Chiappe E and Shirron N and Neven P and Artac M and Kilictas B and Baranseh J and Vicente-Rubio E and Atci M and Amato O and van Duijnhoven F},
  year = {2026},
  journal = {Breast (Edinburgh, Scotland)},
  doi = {10.1016/j.breast.2025.104669},
  url = {https://doi.org/10.1016/j.breast.2025.104669}
}

RIS

TY  - JOUR
TI  - Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.
AU  - Shai A
AU  - Wildiers H
AU  - Venieri C
AU  - Pogoda K
AU  - Linderholm B
AU  - Lambertini M
AU  - Matos L
AU  - De Maio D'Esposito E
AU  - Hajjaji N
AU  - Matos E
AU  - González Cortijo L
AU  - Fotia G
AU  - Fortuna A
AU  - Sella T
AU  - Gouveia H
AU  - Rosset L
AU  - Constantinidou A
AU  - Angeli E
AU  - Cicin I
AU  - Tjan-Heijnen V
AU  - Ruyssers N
AU  - Demasure S
AU  - Abu Remilah A
AU  - Huygh G
AU  - Paluch-Shimon S
AU  - Chiappe E
AU  - Shirron N
AU  - Neven P
AU  - Artac M
AU  - Kilictas B
AU  - Baranseh J
AU  - Vicente-Rubio E
AU  - Atci M
AU  - Amato O
AU  - van Duijnhoven F
PY  - 2026
JO  - Breast (Edinburgh, Scotland)
DO  - 10.1016/j.breast.2025.104669
UR  - https://doi.org/10.1016/j.breast.2025.104669
ER  -

APA

A, S., H, W., C, V., K, P., B, L., M, L., L, M., E, D. M. D., N, H., E, M., L, G. C., G, F., A, F., T, S., H, G., L, R., A, C., E, A., I, C., V, T., N, R., S, D., A, A. R., G, H., S, P., E, C., N, S., P, N., M, A., B, K., J, B., E, V., M, A., O, A., & F, V. D. (2026). Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.. Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2025.104669

Source records